向致癌突变p53和BCL-2用于小细胞肺癌治疗
Victoria Neely1, Alekhya Manchikalapudi1, Khanh Nguyen1
1Philips Institute for Oral Health Research, School of Dentistry, Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USA.
某些小细胞肺癌 (SCLC) 细胞由于突变的p53.3而抵抗venetoclax. 将venetoclax与像ganetespib这样的HSP90抑制剂结合使用,可以通过向BCL-2和瘤原体p53.3来克服这种抵抗.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 小细胞肺癌 (SCLC) 亚型SCLC-A和SCLC-P经常过度表达BCL-2,这是venetoclax治疗的目标.
- 然而,这些SCLC细胞系的一个子集表现出对venetoclax的耐药性,经常与TP53误解突变相关,具有致癌性,功能增强 (Onc-p53) 活动.
- 致癌性p53已与SCLC中减弱化疗疗疗效率有关.
研究的目的:
- 调查Onc-p53在SCLC中venetoclax耐药性的作用.
- 探索在SCLC治疗中同时向BCL-2和Onc-p53的协同潜力.
主要方法:
- 基因组和药物查平台使用大约800个固体瘤细胞系.
- 在SCLC细胞系中对venetoclax敏感性的评估,具有不同的BCL-2和TP53状态.
- 评估Onc-p53下调和HSP90抑制 (使用ganetespib) 对BIM表达和venetoclax敏感性的影响.
主要成果:
- 下调的Onc-p53增加了BIM表达和敏感的SCLC-P细胞venetoclax.
- 用ganetespib准Onc-p53增强了BIM表达,并使SCLC-P和SCLC-A细胞对venetoclax敏感.
- 这些发现表明,Onc-p53有助于增强venetoclax耐药性的机制.
结论:
- 同时针对BCL-2与venetoclax和Onc-p53与HSP90抑制剂,代表了对SCLC的一个子集的有希望的治疗策略.
- 这种组合方法可以克服SCLC-A和SCLC-P亚型中由Onc-p53介导的venetoclax耐药性.
更多相关视频
08:52Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
Published on: November 22, 2021
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Abnormal Proliferation
Tumor Immunotherapy
The Intrinsic Apoptotic Pathway
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
